A detailed history of Black Rock Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,230,371 shares of CRNX stock, worth $336 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,230,371
Previous 5,436,104 14.61%
Holding current value
$336 Million
Previous $254 Million 9.67%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$42.12 - $51.91 $33.5 Million - $41.2 Million
794,267 Added 14.61%
6,230,371 $279 Million
Q1 2024

May 10, 2024

BUY
$34.76 - $46.81 $3.16 Million - $4.26 Million
90,990 Added 1.7%
5,436,104 $254 Million
Q4 2023

Feb 13, 2024

BUY
$25.62 - $37.07 $12.8 Million - $18.5 Million
499,397 Added 10.31%
5,345,114 $190 Million
Q3 2023

Nov 13, 2023

BUY
$15.97 - $30.59 $3.92 Million - $7.5 Million
245,231 Added 5.33%
4,845,717 $144 Million
Q2 2023

Aug 11, 2023

BUY
$15.73 - $23.6 $10.1 Million - $15.2 Million
644,128 Added 16.28%
4,600,486 $82.9 Million
Q1 2023

May 12, 2023

BUY
$15.31 - $21.1 $595,084 - $820,135
38,869 Added 0.99%
3,956,358 $63.5 Million
Q4 2022

Feb 13, 2023

BUY
$15.49 - $19.05 $2.56 Million - $3.15 Million
165,467 Added 4.41%
3,917,489 $71.7 Million
Q3 2022

Nov 14, 2022

SELL
$18.11 - $22.37 $678,418 - $838,002
-37,461 Reduced 0.99%
3,752,022 $73.7 Million
Q2 2022

Aug 12, 2022

BUY
$16.49 - $27.64 $8.12 Million - $13.6 Million
492,703 Added 14.94%
3,789,483 $70.7 Million
Q1 2022

May 12, 2022

BUY
$17.15 - $28.31 $353,461 - $583,469
20,610 Added 0.63%
3,296,780 $72.4 Million
Q4 2021

Feb 10, 2022

BUY
$19.35 - $28.41 $12.8 Million - $18.7 Million
659,331 Added 25.2%
3,276,170 $93.1 Million
Q3 2021

Nov 09, 2021

BUY
$16.88 - $25.23 $395,886 - $591,719
23,453 Added 0.9%
2,616,839 $55.1 Million
Q2 2021

Aug 11, 2021

BUY
$15.9 - $21.15 $41.2 Million - $54.9 Million
2,593,386 New
2,593,386 $48.9 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.